share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K:外國發行人報告
美股SEC公告 ·  10/04 06:30

Moomoo AI 已提取核心訊息

Alterity Therapeutics Limited, a biotechnology company focusing on treatments for neurodegenerative diseases, has announced a change in its share registry service provider. Effective from October 7, 2024, the company will transition from Computershare Investor Services Pty Ltd to Automic Pty Ltd. This change aims to enhance shareholder experience through Automic's secure online investor portal, which offers services such as updating personal details, viewing balances, and transaction history. Shareholders are encouraged to register with Automic's portal to manage their holdings and can contact Automic for support regarding their Alterity holdings. The announcement, authorized by CEO David Stamler, also includes forward-looking statements about the company's drug development program and the progress of clinical trials, specifically mentioning ATH434, a drug compound in development.
Alterity Therapeutics Limited, a biotechnology company focusing on treatments for neurodegenerative diseases, has announced a change in its share registry service provider. Effective from October 7, 2024, the company will transition from Computershare Investor Services Pty Ltd to Automic Pty Ltd. This change aims to enhance shareholder experience through Automic's secure online investor portal, which offers services such as updating personal details, viewing balances, and transaction history. Shareholders are encouraged to register with Automic's portal to manage their holdings and can contact Automic for support regarding their Alterity holdings. The announcement, authorized by CEO David Stamler, also includes forward-looking statements about the company's drug development program and the progress of clinical trials, specifically mentioning ATH434, a drug compound in development.
Alterity Therapeutics Limited,一家專注於神經退行性疾病治療的生物技術公司,宣佈更換股東登記服務提供商。從2024年10月7日起,該公司將從Computershare Investor Services Pty Ltd過渡到Automic Pty Ltd。這一變更旨在通過Automic安全的在線投資者門戶提供股東更好的體驗,該門戶提供諸如更新個人信息、查看餘額和交易歷史等服務。鼓勵股東註冊Automic門戶以管理其持股,並可聯繫Automic獲取有關其Alterity持股的支持。這一由CEO David Stamler授權的公告還包括關於公司藥物開發計劃和臨床試驗進展的前瞻性聲明,特別提到了ATH434,一種正在研發中的藥物化合物。
Alterity Therapeutics Limited,一家專注於神經退行性疾病治療的生物技術公司,宣佈更換股東登記服務提供商。從2024年10月7日起,該公司將從Computershare Investor Services Pty Ltd過渡到Automic Pty Ltd。這一變更旨在通過Automic安全的在線投資者門戶提供股東更好的體驗,該門戶提供諸如更新個人信息、查看餘額和交易歷史等服務。鼓勵股東註冊Automic門戶以管理其持股,並可聯繫Automic獲取有關其Alterity持股的支持。這一由CEO David Stamler授權的公告還包括關於公司藥物開發計劃和臨床試驗進展的前瞻性聲明,特別提到了ATH434,一種正在研發中的藥物化合物。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息